Challenges for the use of MAT2a inhibitors include the variable frequency of the MTAP−/− genotype, which ranges from 55% prevalence in glioblastoma to 2% in colorectal carcinoma, limiting the broader application of these therapeutics (20). Here, MAT2A is linked to colorectal carcinoma.